Preclinical study suggests new approach to reduce COVID-19 death among the elderly — ScienceDaily

The researchers demonstrated in a preclinical study that senolytic drugs significantly reduced mortality upon infection from a beta-coronavirus closely related to SARS-CoV-2 in older mice. The study published in Science was co-led by Laura Niedernhofer, MD, PhD and Paul Robbins, PhD, both professors in the Department of Biochemistry, Molecular Biology and Biophysics and co-directors of the Institute on the Biology of Aging and Metabolism at the U of M Medical School, and Sara Hamilton, PhD, assistant professor in the Department of Laboratory Medicine and Pathology.

Senescent cells — which are cells in the body that are damaged — contribute to inflammation, multiple chronic diseases and age-related loss of resilience, and they accumulate in our body as we age. Senolytic drugs, previously co-discovered by the U of M Medical School and the Mayo Clinic researchers, selectively remove senescent cells from the body.

The COVID-19 pandemic has revealed the pronounced vulnerability of the elderly and chronically-ill to morbidity and mortality induced by SARS-CoV-2. The research team sought to discover why older people are more vulnerable to these adverse outcomes. The team hypothesized it was senescent cells and removing them with senolytics would dial back inflammation and enable an improved response to viral infection.

“We wanted to determine if therapeutically targeting fundamental aging mechanisms, such as cellular senescence, could reduce morbidity and mortality following viral infection,” said Christina Camell, PhD, an assistant professor in the Department of Biochemistry, Molecular Biology and Biophysics, and a first author of the study.

The researchers found that older mice exposed for the first time to a mouse beta-coronavirus experienced nearly 100% mortality, whereas young mice barely got sick. When they treated the older mice with senolytic drugs following infection, their survival rate increased to 50%. The senolytic drugs reduced mortality, cellular senescence and inflammatory markers and increased anti-viral antibodies.

“We have been working on a new approach to help the elderly remain healthy, which is to find therapeutics to treat aging rather than treating each individual disease associated with old age. The fact that senolytics worked to protect old organisms from a viral infection proves that approach is accurate,” Robbins said. “By getting rid of a piece of aging biology, senescent cells, with senolytics, the older mice were able to withstand the stress of infection. This suggests that reducing the burden of senescent cells in ill or elderly individuals could improve their resilience and reduce their risk of dying from COVID-19.”

These results in mice supported the initiation of two clinical trials to reduce mortality in elderly COVID-19 patients. The team also plans to study if senescent cells contribute to the long-hauler effect in many COVID-19 survivors.

This work was supported by the National Institutes of Health, the University of Minnesota Clinical and Translational Science Institute, the University of Minnesota Medical School and the Medical Discovery Team on the Biology of Aging, The Irene Diamond Fund/American Federation on Aging Research Postdoctoral Transition Award, the Fesler-Lampert Chair in Aging Studies, the AFAR Junior Faculty Award, the Paul F. Glenn Center for Biology of Aging Research at Mayo Clinic, the Glenn Foundation, the Connor Fund, Robert J. and Theresa W. Ryan and the Noaber Foundation.

Story Source:

Materials provided by University of Minnesota Medical School. Original written by Kelly Glynn. Note: Content may be edited for style and length.